OFFICIAL HIGHLIGHTS

American Diabetes Association

Conference summaries


COMPLICATIONS

Once-Weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial

Presented by: Gilles R. Dagenais, MD
Université Laval, Québec, QC, Canada
Rafael Diaz, MD
ECLA (EstudiosClínicos Latino América), Rosario, Argentina
Matthew C. Riddle, MD
Oregon Health & Science University, Portland, OR, USA
Hertzel C. Gerstein, MD, MSc
McMaster University & Hamilton Health Sciences, Hamilton, ON, Canada
Helen Colhoun, MD
University of Edinburgh, Edinburgh, UK
Jeffrey L. Probstfield, MD
University of Washington, Seattle, Washington, USA
Lars Rydén, MD, PhD
Karolinska Institutet
  • Three different GLP-1 RAs have been shown to reduce CV outcomes in people with type 2 diabetes at high CV risk with elevated HbA1c levels.
  • The REWIND trial assessed the effect of dulaglutide on major adverse CV events when added to the existing antihyperglycemic regimens in individuals with type 2 diabetes with and without previous CV disease and a wide range of glycemic control.

Dulaglutide is a GLP-1 receptor agonist (GLP-1 RA) approved for the management of hyperglycemia in people with type 2 diabetes. The available evidence has shown that it reduces blood glucose, blood pressure, weight, and albuminuria, and may have other actions suggesting possible cardiovascular (CV) benefits. Moreover, the fact that the CV effects of other GLP-1 RAs have been tested in middle-aged people with high HbA1c levels and a 4% or higher annual risk of CV events highlights the need to test the effect of dulaglutide on CV events in people with a broader CV risk and a wider range of glycemic control.

  • The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial was designed to assess whether the addition of dulaglutide to the diabetes medication regimen of middle-aged and older people with type 2 diabetes safely reduces the incidence of CV outcomes vs. placebo.
  • The long-term effects of dulaglutide on renal outcomes were also assessed in an exploratory analysis.

Type of study, patients, and inclusion criteria

  • Multicenter, randomized, double-blind, placebo-controlled trial at 371 sites in 24 countries.
  • 9,901 participants at least 50 years with type 2 diabetes who had either a previous CV event or CV risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (n=4,949; 1.5 mg) or placebo (n=4,952).
  • Key inclusion criteria included HbA1C ≤9.5%, BMI >23 kg/m2, and age-related criteria (age ≥50 and vascular disease, age ≥55 and subclinical vascular disease, age ≥ 60 and 2 CV risk factors).

Primary outcome

  • The primary outcome was the first occurrence of the composite endpoint of non-fatal myocardial infarction (MI), non-fatal stroke, or death from CV causes (including unknown causes).
  • The renal component of the composite microvascular outcome was defined as the first occurrence of new macroalbuminuria (UACR (urine albumin/creatinine ratio) >33.9 mg/mmol), a sustained decline in eGFR of 30% or more from baseline, or chronic renal replacement therapy.

Cardiovascular outcomes

  • During a median follow-up of 5.4 years (IQR 5.1–5.9), the primary composite outcome occurred in 594 (12.0%) participants at an incidence rate of 2.4 per 100 person-years in the dulaglutide group and in 663 (13.4%) participants at an incidence rate of 2.7 per 100 person-years in the placebo group (HR 0.88, 95% CI 0.79–0.99; P=0.026).
  • All-cause mortality did not differ between groups (536 (10.8%) in the dulaglutide group vs. 592 (12.0%) in the placebo group; HR 0.90, 95% CI 0.80–1.01; P=0.067) (Figure).
  • 2,347 (47.4%) participants assigned to dulaglutide reported a gastrointestinal adverse event during follow-up compared with 1,687 (34.1%) participants assigned to placebo (P <0.0001).

Exploratory renal analyses

  • At baseline, 791 (7.9%) had macroalbuminuria and mean eGFR was 76.9 mL/min/1.73 m² (SD 22.7).
  • During a median follow-up of 5.4 years (IQR 5.1–5.9) comprising 51,820 person-years, the renal outcome developed in 848 (17.1%) participants at an incidence rate of 3.5 per 100 person-years in the dulaglutide group and in 970 (19.6%) participants at an incidence rate of 4.1 per 100 person-years in the placebo group (HR 0.85, 95% CI 0.77–0.93; p=0.0004).
  • The clearest effect was for new macroalbuminuria (HR 0.77, 95% CI 0.68–0.87; P <0.0001), with HRs of 0.89 (0.78–1.01; P=0.066) for sustained decline in eGFR of 30% or more and 0.75 (0.39–1.44; P=0.39) for chronic renal replacement therapy.
  • This long-duration randomized controlled trial of people with type 2 diabetes and only a 31.5% prevalence of previous CV disease showed that dulaglutide reduced the risk of CV outcomes compared with placebo.
  • Long-term use of dulaglutide was associated with reduced composite renal outcomes in patients with type 2 diabetes.

Key Messages/Clinical Perspectives

  • The addition of dulaglutide might be considered for both primary and secondary CV prevention in middle-aged patients with type 2 diabetes and CV risk factors.
  • Future large prospective trials of the effects of dulaglutide on prespecified renal outcomes should be performed to better understand its effects on renal function in patients with preserved and reduced baseline renal function.

 

Trial: NCT01730534



References

References


  1. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-57

Present disclosure: G.R. Dagenais, R. Diaz: the presenters has reported that no relationships exist relevant to the contents of this presentation. M.C. Riddle: Consultant; Self; ADOCIA, DalCor Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline plc., Theracos, Inc.. Research Support; Self; AstraZeneca. H.C. Gerstein: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Other Relationship; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi. H. Colhoun: Advisory Panel; Self; Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Sanofi-Aventis. Research Support; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Roche Pharma, Sanofi-Aventis. Speaker's Bureau; Self; Eli Lilly and Company, Regeneron Pharmaceuticals, Sanofi. Stock/Shareholder; Self; Bayer AG, Roche Pharma. J.L. Probstfield: Other Relationship; Self; Bayer US, Eli Lilly and Company. L. Rydén: Advisory Panel; Self; Boehringer Ingelheim International GmbH. Speaker's Bureau; Self; Bayer AG. Other Relationship; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S.

Written by: Patrick Moore, PhD

Reviewed by: Marco Gallo, MD


All report

Welcome to the ADA 2019 Highlights

Jose C. Florez, MD, PhD
Chair, ADA Scientific Sessions Meeting Planning Committee
The 79th American Diabetes Association’s Scientific Sessions were held in San Francisco, California from June 7-11, 2019. The meeting was attended by over 15,000 professional attendees from 115 countries, … [ Read all ]

CLINICAL TRIALS

Prevention

The Vitamin D and Type 2 Diabetes (D2d) Study—A Multicenter Randomized Controlled Trial for Diabetes Prevention

Presented by: Anastassios G. Pittas, MD; Erin S. LeBlanc, MD, MPH; Myrlene Staten, MD; for the D2d Research Group

Therapeutics

Longitudinal Outcomes in Youth with Type 2 Diabetes—The TODAY2 Study

Presented by: Kimberly L. Drews, MD, PhD; Lorraine E. Levy Katz, MD; Petter Bjornstad, MD; Neil H. White, MD; Jeanie B. Tryggestad, MD; Ruth S. Weinstock, MD, PhD; for the TODAY2 Study Group

Complications

Once-Weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial

Presented by: Gilles R. Dagenais, MD; Rafael Diaz, MD; Matthew C. Riddle, MD; Hertzel C. Gerstein, MD, MSc; Helen Colhoun, MD; Jeffrey L. Probstfield, MD; Hertzel C. Gerstein, MD, MSc

Prevention

PREVIEW: PREVention of diabetes through lifestyle Intervention and population studies in Europe and around the World

Presented by: Ian Macdonald, MD; Edith Feskens, MD, MPH; Margriet Westerterp-Platenga, MD; Mathijs Drummen, MD

Obesity

Results and Comparisons from the RISE Clinical Trial—Adult Medication Study

Presented by: David A. Ehrmann, MD; Kieren J. Mater, MD; Sharon Edelstein, ScM; Steven E. Khan, MD, ChB; Thomas A. Buchanan, MD; Sonia Caprio, MD

Therapeutics

DECLARE-TIMI 58 Trial

Presented by: Itamar Raz, MD; Stephen D. Wiviott, MD; John P. Wilding, MD; Ofri Mosenzon, MD; Lawrence A. Leiter, MD

Therapeutics

The CAROLINA Trial—First Results of the Cardiovascular Outcomes Trial Comparing Linagliptin vs. Glimepiride

Presented by: Julio Rosenstock, MD; Mark A. Espeland, MD; Steven E. Kahn, MD; Nikolaus Marx, MD; Bernard Zinman, MD

Therapeutics

The CREDENCE Trial

Presented by: Rajiv Agarwal, MD; Meg J. Jardine, MD; Bruce Neal, MD; Kenneth W. Mahaffey, MD; Bernard Zinman, MD

Therapeutics

The CARMELINA Trial

Presented by: Steven E. Kahn, MD; Nikolaus Marx, MD; Darren K. McGuire, MD; Christoph Wanner, MD; Mark E. Cooper, MD

Therapeutics

Oral Semaglutide—The PIONEER Program Trials

Presented by: Vanita R. Aroda, MD; Richard E. Pratley, MD; Stephen C. Bain, MA, MD, FRCP; Mansoor Husain, MD, FRCPC; John B. Buse, MD, PhD; Vivian Fonseca, MD
 

CONSENSUS REPORT

Nutrition

ADA Nutrition Therapy for Adults with Diabetes—2019 Consensus Report

Presented by: Alison B. Evert, MD; Janice MacLeod, MA, RDN, CDE; William S. Yancy, Jr., MD, MHS; W. Timothy Garvey, MD; Ka Hei Karen Lau, MS, RD, LDN, CDE; Christopher D. Gardner, PhD; Kelly M. Rawlings, MS
 

SYMPOSIA

Complications

Cardiovascular and Renal Protection in Diabetes—Emphasis on SGLT2 Inhibitors and GLP-1 Receptor Agonists

Presented by: Julie A. Lovshin, MD, PhD; Jens J. Holst, MD, DMSc; David C. Wheeler, MD

Physiology/Obesity

Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)—The Overlooked Complications of Type 2 Diabetes

Presented by: Elisabetta Bugianesi, MD, PhD; Zobair Younossi, MD, MPH; Kenneth Cusi, MD

Complications

Controversies in the Evaluation and Management of Dyslipidemia in Patients with Diabetes

Presented by: Amy Sanghavi Shah, MD, MS; Dan Streja, MD; Savitha Subramanian, MD; Lisa Tannock, MD

Complications

Hypoglycemia in Type 2 Diabetes

Presented by: Kamlesh Khunti, MD, PhD, FRCGP, FRCP; Elizabeth Selvin, PhD, MPH; Frans Pouwer, PhD; Sophia Zoungas, MBBS (Hons), PhD, FRACP